Melinta Therapeutics reports the initiation of an international Phase 3 trial comparing Baxdela (delafloxacin), an investigational fluoroquinolone, to moxifloxacin for the treatment of hospitalized patients with radiographic evidence of community-acquired bacterial pneumonia.

The primary efficacy endpoint is improvement at 96 hours after the first dose in at least two of the following symptoms: chest pain, frequency or severity of cough, amount of productive sputum, and difficulty breathing. Additional efficacy and safety measures will also be captured.

The U.S. FDA has designated Baxdela as a Qualified Infectious Disease Product for community-acquired bacterial pneumonia.